Cargando…
Immunotherapy earns its spot in the ranks of cancer therapy
Since it became clear that all cancer cells express tumor-specific and tumor-selective antigens generated by genetic alterations and epigenetic dysregulation, the immunology community has embraced the possibility of designing therapies to induce targeted antitumor immune responses. The potential the...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280881/ https://www.ncbi.nlm.nih.gov/pubmed/22330682 http://dx.doi.org/10.1084/jem.20112275 |
_version_ | 1782223878834094080 |
---|---|
author | Pardoll, Drew Drake, Charles |
author_facet | Pardoll, Drew Drake, Charles |
author_sort | Pardoll, Drew |
collection | PubMed |
description | Since it became clear that all cancer cells express tumor-specific and tumor-selective antigens generated by genetic alterations and epigenetic dysregulation, the immunology community has embraced the possibility of designing therapies to induce targeted antitumor immune responses. The potential therapeutic specificity and efficacy of such treatments are obvious to anyone who studies the exquisite specificity and cytocidal potency of immune responses. However, the value assigned to a therapeutic modality by the oncology community at large does not depend on scientific principle; all that matters is how patients respond. The bar for the ultimate acceptance of a therapy requires more than anecdotal clinical responses; rather, the major modalities of cancer therapeutics, including surgery, chemotherapy, radiation therapy, and, more recently, drugs targeting oncogenes, have earned their place only after producing dramatic frequent clinical responses or demonstrating statistically significant survival benefits in large randomized phase 3 clinical trials, leading to FDA approval. Although tumor-targeted antibodies have certainly cleared this bar, immunotherapies aimed at harnessing antitumor cellular responses have not—until now. |
format | Online Article Text |
id | pubmed-3280881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-32808812012-08-13 Immunotherapy earns its spot in the ranks of cancer therapy Pardoll, Drew Drake, Charles J Exp Med Perspective Since it became clear that all cancer cells express tumor-specific and tumor-selective antigens generated by genetic alterations and epigenetic dysregulation, the immunology community has embraced the possibility of designing therapies to induce targeted antitumor immune responses. The potential therapeutic specificity and efficacy of such treatments are obvious to anyone who studies the exquisite specificity and cytocidal potency of immune responses. However, the value assigned to a therapeutic modality by the oncology community at large does not depend on scientific principle; all that matters is how patients respond. The bar for the ultimate acceptance of a therapy requires more than anecdotal clinical responses; rather, the major modalities of cancer therapeutics, including surgery, chemotherapy, radiation therapy, and, more recently, drugs targeting oncogenes, have earned their place only after producing dramatic frequent clinical responses or demonstrating statistically significant survival benefits in large randomized phase 3 clinical trials, leading to FDA approval. Although tumor-targeted antibodies have certainly cleared this bar, immunotherapies aimed at harnessing antitumor cellular responses have not—until now. The Rockefeller University Press 2012-02-13 /pmc/articles/PMC3280881/ /pubmed/22330682 http://dx.doi.org/10.1084/jem.20112275 Text en © 2012 Pardoll and Drake This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). |
spellingShingle | Perspective Pardoll, Drew Drake, Charles Immunotherapy earns its spot in the ranks of cancer therapy |
title | Immunotherapy earns its spot in the ranks of cancer therapy |
title_full | Immunotherapy earns its spot in the ranks of cancer therapy |
title_fullStr | Immunotherapy earns its spot in the ranks of cancer therapy |
title_full_unstemmed | Immunotherapy earns its spot in the ranks of cancer therapy |
title_short | Immunotherapy earns its spot in the ranks of cancer therapy |
title_sort | immunotherapy earns its spot in the ranks of cancer therapy |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280881/ https://www.ncbi.nlm.nih.gov/pubmed/22330682 http://dx.doi.org/10.1084/jem.20112275 |
work_keys_str_mv | AT pardolldrew immunotherapyearnsitsspotintheranksofcancertherapy AT drakecharles immunotherapyearnsitsspotintheranksofcancertherapy |